Figure S1


Patients treated with Chemo-IO or IO without
EGFR or *ALK*-sensitizing mutations
N=3777
N=2,903 excluded
Non-adenocarcinoma;
PD-L1<1%; or line of therapy >1
N=874
Clinical analysis cohort
N=874
Chemo-IO
N=397
IO
N=477
Genomic analysis cohort
N=579
Chemo-IO
N=263
IO
N=316